Wegovy® Pen with Ongoing Care

Wegovy® is a once-weekly injectable medication that contains semaglutide, a GLP-1 receptor agonist. It is administered using a prefilled, single-use pen. GLP-1 medications work by mimicking a naturally occurring hormone that regulates appetite, insulin response, and gastric emptying. By enhancing satiety and reducing hunger signaling, Wegovy® helps decrease overall caloric intake. Beyond appetite regulation, semaglutide also influences metabolic pathways related to blood sugar control, inflammation, and cardiometabolic risk. Treatment is structured with a medically supervised program to ensure safe dose titration and monitoring.

Wegovy® is the brand name for semaglutide when prescribed specifically for chronic weight management at higher doses. Semaglutide is the active ingredient. It is also used in other medications, such as Ozempic®, which is FDA-approved for type 2 diabetes at different dosing levels. Wegovy® uses a specific titration schedule designed for long-term weight and metabolic management. While the active molecule is the same, dosing, indications, and prescribing frameworks differ.

The most common side effects of Wegovy® are gastrointestinal and may include: nausea; vomiting; diarrhea; constipation; and abdominal discomfort. These effects are usually most noticeable during dose increases and often improve over time. Less common but more serious risks include gallbladder issues, pancreatitis, and potential thyroid C-cell tumors in animal studies. Wegovy® is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or MEN2. Medical supervision and appropriate screening are important for safe use.

Many patients notice appetite changes within the first few weeks of treatment, even at starter doses. Clinically meaningful weight changes typically become more noticeable after several weeks to a few months, as doses are gradually increased toward the maintenance level. Because Wegovy® is designed for long-term metabolic management, results are generally progressive rather than immediate. Consistency and appropriate dose titration are key factors in outcomes.

The GLP-1 membership is designed to support GLP-1 therapy as ongoing medical care, not a one-time prescription. Membership includes clinician evaluation and prescribing, personalized dosing and titration over time, and continued clinical oversight as your body responds to treatment. Members also receive support for side-effect management, nutrition as appetite changes, and muscle-preservation strategies to support long-term metabolic health. The membership includes ongoing biomarker and lifestyle tracking, with labs incorporated into care when clinically appropriate to monitor metabolic health and guide treatment decisions over time. Labs are not required to start treatment, but are an important part of Healthspan’s longevity-focused approach as therapy progresses. Membership starts at $99 per month. GLP-1 medications are billed separately based on the prescription and pharmacy used. As part of the membership, Healthspan helps coordinate prescriptions, refills, and medication logistics as treatment evolves.

No. Healthspan clinicians prescribe GLP-1 therapy for a range of health goals, not weight loss alone. GLP-1s are increasingly used to support: metabolic health and insulin sensitivity; cardiometabolic risk reduction; appetite regulation and energy balance; long-term health and aging-related outcomes. Your clinician evaluates your goals and health context to determine which GLP-1 treatment option is appropriate and how it should be managed over time.